MSLN overexpression in cancers enables tumor-specific targeting using monoclonal antibodies, as well as chimeric antigen receptor (CAR)-T cells containing single-chain variable domain fragments (scFvs) that bind to MSLN [3]. This evidence concerns the gene MSLN and cancer.